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INTRODUCTION
Type 1 diabetes is associated with sub-
stantially increased rates of morbidity and
mortality, accounting for costs exceeding
$14.9 billion in health care costs in the
U.S. each year (1–11). It is characterized
by decreased insulin secretion and severe
hyperglycemia, which can lead to ketoaci-
dosis, coma and death. The disease patho-
genesis is attributed to immune-mediated
destruction of the insulin-producing β-
cells of pancreatic islets. Histopathological
findings in type 1 diabetes includes in-
flammation and destruction of pancreatic
islets with infiltration of macrophages,
T cells and other immune cells (12–19).
Titers of autoreactive antibodies are sig-
nificantly increased in patients suffering
from type 1 diabetes, including antibodies
specific for insulin (IAA), glutamic acid
decarboxylase (GAD), protein tyrosine
phosphatase (ICA512 or IA2A) and zinc
transporter protein (ZnT8) (20–23). There
are currently no effective treatments for
type 1 diabetes. Anti–B-cell antibodies
(rituximab), anti-CD3 antibodies 
(otelixizumab and teplizumab) targeting
T cells and the Diamyd vaccine (GAD 
immunotherapy) have all failed to meet
endpoints in recent clinical trials (24–30).
Recent advances in understanding neu-
ral control of innate immunity reveal that
neural reflexes, including the inflamma-
tory reflex and the cholinergic antiinflam-
matory pathway, control cytokine release
and inflammation (31–39). The choliner-
gic antiinflammatory pathway is defined
as a vagus nerve signal that culminates
on T-cell acetylcholine release and activa-
tion of α7 nicotinic acetylcholine receptor
(α7nAChR) on splenic macrophages,
which inhibits proinflammatory cytokine
release (40–44). Nerve stimulation and
administration of α7 receptor agonists are
in clinical development for treatment of
inflammatory diseases (39,45–47). Recent
evidence also links activation of the
cholinergic antiinflammatory pathway to
a reduction in antibody production in
spleen, specifically lower antibody titers
and B-cell activity during Streptococcus
pneumoniae infection (48). Here we rea-
soned that the cholinergic antiinflamma-
tory pathway would attenuate inflamma-
tion and serum antibody titers in murine
type 1 diabetes.
Galantamine, a centrally acting acetyl-
cholinesterase (AChE) inhibitor clinically
approved to treat Alzheimer’s disease
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(49,50), is an activator of the cholinergic
antiinflammatory pathway (35,51). We re-
cently reported that galantamine treat-
ment of mice with high fat diet–induced
obesity significantly alleviates weigh gain,
obesity-associated inflammation, hyper-
glycemia and insulin resistance (52). The
nonobese diabetic (NOD) mouse is a
model of type 1 diabetes, spontaneously
developing antibodies against self-
 antigens, with islet infiltration starting at
3–4 wks, leading to later islet destruction
and hyperglycemia around 16–18 wks
(53). In addition, similar antibodies, as ob-
served in humans, have been described in
the nonobese diabetic (NOD) mouse
model of type 1 diabetes (54–56). Accord-
ingly, here we administered galantamine
to NOD mice beginning at a preclinical
stage and measured blood glucose and
serum antibodies. We found that galanta-
mine administration attenuates type 1 
diabetes–associated hyperglycemia, con-
fers protection against islet inflammation
and decreases serum titers of diabetes-
 related autoimmune antibodies.
MATERIALS AND METHODS
Animals
NOD (4–5 wks old) and Balb/c (6–8
wks old) mice were obtained from The
Jackson Laboratory. Food and water
were available ad libitum. Mice were used
in subsequent experiments after at least a
14-d adaptation period. All procedures
were performed in accordance with the
National Institutes of Health (NIH)
guidelines (57) under protocols approved
by the Institutional Animal Care and Use
Committee (IACUC) of the Feinstein In-
stitute for Medical Research.
Cytokine and Antibody Determination
Balb/c mice were injected intraperi-
toneally with 100 μg keyhole limpet he-
mocyanin (KLH) (Calbiochem) + 50% Im-
ject Alum (Thermo Scientific) in 200 μL
saline two times, 2 wks apart. Two weeks
after the second injection, 4 mg/kg galan-
tamine was injected intraperitoneally.
Splenocytes were harvested 4 h later, and
erythrocytes were lysed with red blood
cell lysis buffer (Sigma-Aldrich) and 
cultured in RPMI, HEPES, penicillin/
streptomycin, L-glutamine, 1% nonessen-
tial amino acids and β-mercaptoethanol.
Cells were exposed to increasing concen-
trations of KLH for 48 h, and media were
analyzed for cytokine and antibody con-
tent. Cytokines were measured by multi-
plex enzyme-linked immunosorbent
assay (ELISA) (Quansys), and IgG anti-
bodies were measured by ELISA. Briefly,
plates were coated with 20 μg/mL KLH
antigen in phosphate-buffered saline
(PBS) (Life Technologies) overnight, fol-
lowed by blocking with 1% bovine serum
albumin (BSA) in PBS for 2 h. Plates were
washed with PBS + 0.01% Tween-20
(PBST) three times. Blood collected by
capillary tube from nicked mouse tail was
spun at 5,000g, and then serum was ex-
tracted and diluted 1:1,000 to 1:10,000 in
PBS + BSA. A total of 100 μL diluted
serum was incubated on coated plates for
1 h at room temperature and was then
washed three times with PBST. A 1:2,000
dilution of horseradish peroxidase–
 conjugated sheep anti-mouse IgG (GE
Healthcare) was added to the plates for
1 h at room temperature and was then
washed again. Plates were then devel-
oped using OptEIA TMB substrate (BD
Biosciences), and optical density at
450 nm was measured. Total IgE levels
were determined by ELISA with rat anti-
mouse IgE (BD Biosciences) coated plates,
probed with biotinylated rat anti-mouse
IgE antibody, followed by horseradish
peroxidase–conjugated streptavidin.
Drug Administration
Five-week-old female NOD/ShiLtJ
mice were injected intraperitoneally with
1 mg/kg galantamine (Calbiochem) or
vehicle control in 200 μL normal saline,
daily, until the end of the experiment.
Blood glucose was measured once weekly
by using a Freestyle Freedom Lite meter
(Abbott). Mice were deemed diabetic
after 2 consecutive blood glucose read-
ings >200 mg/dL. For therapeutic exper-
iments, NOD/ShiLtJ mice with overt di-
abetes (blood glucose >200 mg/dL for
2 wks in a row, 16–22 wks of age) were
injected intraperitoneally with 1 mg/kg
galantamine or saline, daily, with moni-
tored blood glucose. At the end of the ex-
periment, mice were euthanized with
CO2, and pancreas, spleen and serum
were collected and processed for further
analyses.
Tissue Processing and Insulitis Scores
Mice were euthanized at 17 wks, and
pancreas was fresh-frozen in optimal cut-
ting temperature (O.C.T.) medium. Dia-
betic and nondiabetic mice were both in-
cluded in the analysis of insulitis. The 5-
to 7-μm slices were obtained by cryostat
sectioning, mounted and fixed in acetone,
allowed to dry at room temperature and
stained with Mayer’s hematoxylin for 5
min. Insulitis was scored by using a
bright-field microscope in double-blinded
manner (blinded to both treatment groups
and diabetic state). At least 50 islets from
at least three disparate sections of each
mouse pancreas were then scored as fol-
lows: 0, no insulitis; 1, peri-insulitis; 2,
moderate (<70%) insulitis; 3, complete
(>70%) insulitis (Supplemental Figure S1).
Antibody Determination
Plates were coated with antigens includ-
ing insulin (human insulin; Sigma), his-
tone II-A (from calf thymus; Sigma),
myelin basic protein (MBP) (from mouse;
Sigma), myelin oligodendrocyte glycopro-
tein (MOG) (immunodominant epitope of
mouse MOG; Sigma) and deoxyribonu-
cleic acid (DNA) (from calf thymus;
Sigma). IgG levels were determined by
ELISA as previously described using
plates coated with each respective antigen.
Statistics
Blood glucose, KLH antibody re-
sponses and cytokine responses were an-
alyzed by two-way analysis of variance
(ANOVA) followed by Bonferroni
posttest. Diabetes-onset survival curves
were analyzed by log-rank (Mantel-Cox).
Islet scores were analyzed by the χ2 test.
All tests with a p value of <0.05 were
considered statistically significant. Statis-
tical analyses were performed by using
Graphpad Prism 6 software. Unless oth-
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erwise stated, all numbers are given as
average ± standard error of the mean.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Galantamine Attenuates Antibody
Release by Splenocytes
We first examined the effect of galanta-
mine administration on splenocyte anti-
body release. Mice were immunized in-
traperitoneally with keyhole limpet
hemocyanin in alum twice, 2 wks apart.
Fourteen days after the second immu-
nization, mice were injected with galant-
amine (4 mg/kg) or saline intraperi-
toneally 4 h before euthanasia, and
isolated splenocytes were cultured in the
presence of KLH in vitro. Splenocytes
from mice administered galantamine
produced less KLH-specific IgG, while
producing more total IgE (Figure 1). In
addition, galantamine administration re-
sulted in reduced interleukin (IL)-4 and
IL-6, but not IL-2, release by splenocytes
(Figure 2). No changes in cell numbers
were observed.
Galantamine Reduces Serum Levels
of Anti-Insulin Antibodies in NOD Mice
NOD mice have elevated levels of au-
toantibodies (55). To investigate the effect
of galantamine on serum antibody levels,
titers of anti-insulin, anti-histone, anti-
DNA, anti-MOG and anti-MBP antibodies
were measured in galantamine-
 administered and control NOD mice. 
IgG antibodies specific to insulin were
significantly reduced in galantamine-
 administered animals (Figure 3A), whereas
antibodies directed against histone,
DNA, MOG and MBP were unaffected
(Figures 3B–E). These results indicate a se-
lective suppressive effect of galantamine
administration on insulin-specific anti-
body production in this model.
Galantamine Prevents Hyperglycemia
and Diabetes Onset
To study the preventative effects of
galantamine in type 1 diabetes, 4- to 
Figure 1. Galantamine alters antibody responses in immunized mice. KLH immunized mice
were administered galantamine (4 mg/kg) or saline 4 h before death. Splenocytes were ex-
tracted, plated at 2 × 105 in 96-well plates and incubated with indicated μg/well KLH. KLH-
specific IgG (A) and total IgE (B) was determined by ELISA. Galantamine affected antibody
levels (IgG, p < 0.05; IgE, p < 0.01 by two-way ANOVA; *p < 0.05 by Bonferroni posttest).
Figure 2. Galantamine alters cytokine responses in immunized mice. KLH immunized mice were
administered galantamine (4 mg/kg) or saline 4 h before death. Splenocytes were extracted,
plated at 2 × 105 in 96-well plates and incubated with indicated μg/well KLH. Cytokines were
determined on d 7 by Quansys multiplex ELISA. (A) Galantamine did not significantly affect 
IL-2. (B) IL-4 (p < 0.001) and IL-6 (p < 0.0001) were significantly different in galantamine-treated
animals (two-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, by Bonferroni posttest).
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5-wk-old NOD mice were administered
1 mg/kg galantamine (n = 11) or saline
(n = 10) intraperitoneally, 200 μL daily
for 20 wks. Blood glucose was moni-
tored weekly to determine the onset of
hyperglycemia, defined as glucose 
>200 mg/dL. Mice administered galanta-
mine did not develop hyperglycemia
until wk 19, whereas almost all mice ad-
ministered saline rapidly developed hy-
perglycemia by wk 14 (Figure 4A). The
average glucose levels in saline-
 administered animals was 226.6 ± 
60.3 mg/dL by wk 14; similar levels were
not reached in galantamine-administered
animals until wk 19 (227.8 ± 52.3 mg/dL)
(Figure 4A). Additionally, the prevalence
of diabetes (two consecutive blood 
glucose levels >200 mg/dL) in mice ad-
ministered galantamine was lower (Fig-
ure 4B, p < 0.05). Galantamine-adminis-
tered mice that did develop diabetes
rapidly progressed to high levels of
blood glucose (data not shown).
To determine the efficacy of galanta-
mine in treating established diabetes,
NOD mice with 2 consecutive weeks of
blood glucose >200 mg/dL were admin-
istered 1 mg/kg galantamine daily.
Galantamine treatment did not signifi-
cantly alter blood glucose levels, com-
pared with vehicle treatment (Supple-
mentary Figure S1). Together, these
results indicate that galantamine in the
context of preclinical type 1 diabetes at
relatively early stages of disease progres-
sion is efficacious in delaying onset of
hyperglycemia.
Galantamine Attenuates Pancreatic
Islet Inflammation
To determine to effect of galantamine
on immune cell infiltration in pancreatic
islets, pancreata from 17-wk-old female
NOD mice administered 1 mg/kg galan-
tamine or saline intraperitoneally daily
were investigated by using histochemical
methods. The 7-μm sections were ob-
tained from throughout the pancreas, at
least 100 μm apart. Insulitis was scored
from 0 to 3, as indicated in Figure 5A.
Administration of galantamine reduced
the severity of insulitis (Figure 5B) and
improved the overall insulitis score in
galantamine-administered animals (Fig-
ure 5C, χ2 p < 0.0005).
DISCUSSION
Here, we show that administration of
the acetylcholinesterase inhibitor galant-
amine (35,51,58) delays elevation of
blood glucose levels and onset of dia-
betes in the NOD model. In this disease
model, galantamine reduces pancreatic
islet inflammation and lowers disease-
specific antibody levels without reducing
levels of other tested IgG antibodies. Fur-
thermore, splenocytes derived from
galantamine-administered mice released
less IL-4, IL-6 and IgG in response to
antigen re-exposure in vitro.
The observation that splenocytes de-
rived from galantamine-administered
mice released less IgG and higher IgE lev-
els in response to immunized antigen in
vitro suggests that galantamine stimulates
class-switching of B cells from IgG to IgE.
In addition, the lower IL-4 and IL-6 secre-
tion by splenocytes from galantamine-ad-
ministered animals after antigen exposure
suggests an environment less supportive
of B-cell antibody release, including sup-
pression of Th2 helper T cells. These find-
ings highlight a previously unrecognized
antiinflammatory effect of galantamine in
preclinical type 1 diabetes.
Autoimmunity in NOD mice is initi-
ated in the pancreatic lymph nodes, but
not in the spleen, at 2–3 wks of age (59).
Treatment starting from 5 wks of age
could influence a mechanism that slows
the progression of insulitis and ulti-
mately the onset of clinical diabetes sepa-
rate from the initial priming for autoim-
munity to islet autoantigens. We
examined cytokine content by ELISA
from pancreatic samples at 12 wks of age
Figure 3. Galantamine administration reduces levels of circulating pathogenic anti-insulin
antibodies. Serum from galantamine- or saline-administered was applied to ELISA plates
coated with antigens and then probed with anti-mouse antibodies. Serum anti-insulin an-
tibodies were reduced in animals administered galantamine (A) (p > 0.05), but other
common NOD autoantibodies were not affected (B–E).
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after 8 wks of galantamine administra-
tion. The lysate of these samples in-
cluded embedded pancreatic lymph
nodes. We found no difference in levels
of interferon (IFN)-γ, IL-17, monocyte
chemotactic protein 1 (MCP-1) or IL-1β
(data not shown).
Changes in cellular populations could
be an important component of galanta-
mine’s antiinflammatory effects. To ex-
amine changes in populations, we ob-
tained single cell isolates from both
spleen and total pancreas, including
lymph nodes, taken from mice adminis-
tered galantamine for 8 wks. We exam-
ined CD3+CD4+, CD3+CD4+FoxP3+ and
CD3+CD8+ populations by flow cytome-
try. We observed no difference in per-
centages of these populations in treated
animals compared with vehicle control in
both spleen and pancreas (data not
shown). Fewer cells were observed in the
pancreata of galantamine-treated animals
(data not shown). It is plausible that
galantamine may suppress the inflamma-
tory activity of the immune cells, but
does not alter the immune cell composi-
tion. The specific effect of galantamine
on cellular function remains to be eluci-
dated, and additional analyses would
provide useful data.
Galantamine has previously been
shown to exert antiinflammatory effects
through brain-mediated and vagus
nerve–dependent signaling (35,51). The
vagus nerve innervates the pancreas, and
vagus nerve cholinergic output controls
pancreatic endocrine and exocrine secre-
tion (60–62). A role for the vagus nerve
has also been shown in suppressing pan-
creatic inflammation; surgical transection
of the vagus nerve (vagotomy) results in
exacerbated murine pancreatitis, thus in-
dicating a tonic antiinflammatory role of
these innervations (63). The vagus nerve
also innervates the liver, and it is known
that vagus nerve–mediated signaling
suppresses hepatic glucose production
(64–66), one of the main determinants of
fasting blood glucose levels. We suggest
that galantamine-mediated activation of
the vagus nerve reduces pancreatic in-
flammation and delays onset of diabetes.
Figure 4. Galantamine delays the onset of hyperglycemia and diabetes. The 1 mg/kg
galantamine (n = 11) or saline (n = 10) was administered intraperitoneally daily to NOD
mice beginning at 5 wks of age. Blood glucose levels were measured weekly, with two
successive weeks of blood glucose >199 mg/dL, indicating onset of diabetes. Administra-
tion of galantamine (A) significantly reduced the average blood glucose over time (p <
0.05, two-way ANOVA), and (B) significantly delayed onset of diabetes (p < 0.05, Mantel-
Cox, results of two combined experiments).
Figure 5. Daily administration of galantamine decreases islet infiltration by immune cells. (A)
Insulitis scoring scheme examplars. Islets with no infiltrating mononuclear cells were scored as
0, peri-islet inflammation only = 1, moderate intra-islet inflammation occupying <70% of the
islet = 2, severe-complete intra-islet inflammation occupying >70% of the islet = 3. (B, C) Pan-
creata from 16-wk-old NOD mice injected intraperitoneally with saline or galantamine from
5 wks of age were isolated and frozen in OCT media and then sliced at 10 μm. At least 50
total islets from three disparate areas of each pancreas were scored blindly. Administration
of galantamine (B) reduced the severity of insulitis in NOD mice (representative images), as
well as (C) improved the overall level of insulitis in the pancreas (n = 5, χ2 p < 0.0005).
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In this context, it is possible that meta-
bolic effects of vagus nerve activation on
hepatic glucose release may also play a
role (67). Future studies should address
the role of these and other mechanisms
in mediating galantamine efficacy in
type 1 diabetes.
CONCLUSION
Galantamine is in clinical use for treat-
ment of Alzheimer’s disease patients in
the United States and has been used for
decades in Europe in treating myasthenia
gravis and Alzheimer’s disease and in
children with autism spectrum disorders
(49,50,68). This abundant clinical experi-
ence in adult and pediatric populations
should facilitate potential experimental
use of galantamine in the treatment of
type 1 diabetes. Other therapeutic ap-
proaches, including β-cell transplantation
or β-cell regeneration have been explored
(69–76). In light of our current findings,
it would be interesting to further study
whether galantamine treatment in com-
bination with islet restoration would im-
prove clinical outcomes in established
type 1 diabetes.
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